In this study, we evaluated the durability of various SARS-CoV-2-specific antibodies by comparing their titers, decay rates, and half-lives in the blood samples collected from individuals 2 and 12 months after COVID-19 onset, and further analyzed the relationship between the frequencies of CD4+ or CD8+ and the decay rates of SARS-CoV-2-specific antibodies. The gene discussed is CD8A; the disease is COVID-19.